Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Regulatory News (OXB)

Share Price Information for Oxford Biomedica (OXB)

Share Price is delayed by 15 minutes
Get Live Data
625.00    -5.00 (-0.79%)
Bid:
618.00
Ask:
621.00
Spread: 3.00 (0.485%)
Market Cap: £756.31m
OXB Live PriceLast checked at - London Stock Exchange

Intraday Oxford Biomedica Share Chart

Rule 2.9 Announcement

5 Feb 2026 07:00

RNS Number : 7874R
Oxford Biomedica PLC
05 February 2026
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.

FOR IMMEDIATE RELEASE

 

5 February 2026

Oxford Biomedica plc ("OXB" or the "Company")

Rule 2.9 Announcement

In accordance with Rule 2.9 of the City Code on Takeovers and Mergers (the "Code"), the Company confirms that, as at close of business on 4 February 2026, its issued share capital consisted of 120,852,814 ordinary shares of £0.50 each, each carrying one vote ("Ordinary Shares"). There are no Ordinary Shares held in treasury.

The International Securities Identification Number for the Ordinary Shares is GB00BDFBVT43. The Company's Legal Entity Identifier is 213800S1GVQNXQ15K851.

Enquiries:

Oxford Biomedica plc:

+44 (0) 1865 783 000

Lucy Crabtree - Chief Financial Officer

 

 

Evercore Partners International LLP (Financial Adviser to OXB)

+44 (0) 20 7653 6000

Julian Oakley

Simon Elliott

Wladimir Wallaert

Harrison George

 

 

Jefferies International Limited (Financial Adviser and Corporate Broker to OXB)

+44 (0) 20 7029 8000

Philip Yates

Sam Barnett

Gil Bar-Nahum

William Brown

 

 

ICR Healthcare:

+44 (0) 20 3709 5700

Mary-Jane Elliott / Angela Gray / Davide Salvi

 

 

IMPORTANT NOTICES

Evercore Partners International LLP ("Evercore"), which is authorised and regulated by the Financial Conduct Authority ("FCA") in the UK, is acting exclusively as financial adviser to OXB and no one else in connection with the matters described in this announcement and will not be responsible to anyone other than OXB for providing the protections afforded to clients of Evercore nor for providing advice in connection with the matters referred to herein. Neither Evercore nor any of its subsidiaries, branches or affiliates owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of Evercore in connection with this announcement, any statement contained herein, any offer or otherwise. Apart from the responsibilities and liabilities, if any, which may be imposed on Evercore by the Financial Services and Markets Act 2000, or the regulatory regime established thereunder, or under the regulatory regime of any jurisdiction where exclusion of liability under the relevant regulatory regime would be illegal, void or unenforceable, neither Evercore nor any of its affiliates accepts any responsibility or liability whatsoever for the contents of this announcement, and no representation, express or implied, is made by it, or purported to be made on its behalf, in relation to the contents of this announcement, including its accuracy, completeness or verification of any other statement made or purported to be made by it, or on its behalf, in connection with OXB or the matters described in this announcement. To the fullest extent permitted by applicable law, Evercore and its affiliates accordingly disclaim all and any responsibility or liability whether arising in tort, contract or otherwise (save as referred to above) which they might otherwise have in respect of this announcement, or any statement contained herein.

Jefferies International Limited ("Jefferies"), which is authorised and regulated by the FCA in the UK, is acting exclusively as financial adviser to OXB and no one else in connection with the matters described in this announcement and will not regard any other person as its client in relation to the matters in this announcement and will not be responsible to anyone other than OXB for providing the protections afforded to clients of Jefferies nor for providing advice in relation to any matter referred to in this announcement. Neither Jefferies nor any of its affiliates (nor their respective directors, officers, employees or agents) owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of Jefferies in connection with this announcement, any statement contained herein or otherwise.

The person responsible for arranging for the release of this announcement on behalf of OXB is Natalie Walter, Chief Legal Officer and Company Secretary.

DISCLOSURE REQUIREMENTS OF THE CITY CODE ON TAKEOVERS AND MERGERS (THE "CODE")

Under Rule 8.3(a) of the Code, any person who is interested in 1 per cent. or more of any class of relevant securities of an offeree company or of any securities exchange offeror (being any offeror other than an offeror in respect of which it has been announced that its offer is, or is likely to be, solely in cash) must make an Opening Position Disclosure following the commencement of the offer period and, if later, following the announcement in which any securities exchange offeror is first identified.

An Opening Position Disclosure must contain details of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any securities exchange offeror(s). An Opening Position Disclosure by a person to whom Rule 8.3(a) applies must be made by not later than 3.30 pm (London time) on the 10th business day following the commencement of the offer period and, if appropriate, by not later than 3.30 pm (London time) on the 10th business day following the announcement in which any securities exchange offeror is first identified. Relevant persons who deal in the relevant securities of the offeree company or of a securities exchange offeror prior to the deadline for making an Opening Position Disclosure must instead make a Dealing Disclosure.

Under Rule 8.3(b) of the Code, any person who is, or becomes, interested in 1 per cent. or more of any class of relevant securities of the offeree company or of any securities exchange offeror must make a Dealing Disclosure if the person deals in any relevant securities of the offeree company or of any securities exchange offeror. A Dealing Disclosure must contain details of the dealing concerned and of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any securities exchange offeror(s), save to the extent that these details have previously been disclosed under Rule 8. A Dealing Disclosure by a person to whom Rule 8.3(b) applies must be made by not later than 3.30 pm (London time) on the business day following the date of the relevant dealing.

If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire or control an interest in relevant securities of an offeree company or a securities exchange offeror, they will be deemed to be a single person for the purpose of Rule 8.3.

Opening Position Disclosures must also be made by the offeree company and by any offeror and Dealing Disclosures must also be made by the offeree company, by any offeror and by any persons acting in concert with any of them (see Rules 8.1, 8.2 and 8.4 of the Code).

Details of the offeree and offeror companies in respect of whose relevant securities Opening Position Disclosures and Dealing Disclosures must be made can be found in the Disclosure Table on the Takeover Panel's website at www.thetakeoverpanel.org.uk, including details of the number of relevant securities in issue, when the offer period commenced and when any offeror was first identified. You should contact the Panel's Market Surveillance Unit on +44 (0)20 7638 0129 if you are in any doubt as to whether you are required to make an Opening Position Disclosure or a Dealing Disclosure.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RTTUSSURNAUURUR
Date   Source Headline
30th Jun 201710:38 amRNSRefinancing of Debt Facility
23rd Jun 201710:12 amRNSDirector Dealings / Market Share Purchase
14th Jun 20173:00 pmRNSFindings from Phase II JULIET Study
7th Jun 20177:00 amRNSOXB notes FDA Advisory Committee to review CTL019
2nd Jun 20177:00 amRNSOXB to Present at Jefferies Healthcare Conference
1st Jun 201712:22 pmRNSTotal Voting Rights
24th May 20171:55 pmRNSDirector/PDMR Shareholding
23rd May 20172:03 pmRNSResult of AGM
4th May 20178:46 amRNSTotal Voting Rights
28th Apr 20177:00 amRNSAnnual Report and Accounts & AGM Notification
24th Apr 201710:17 amRNSDirector/PDMR Shareholding
4th Apr 20177:00 amRNSHolding(s) in Company
3rd Apr 20179:11 amRNSTotal Voting Rights
31st Mar 20177:15 amRNSHardman: Delivering commercial gene-therapy vector
30th Mar 20177:02 amRNSBLA filing for CTL019
27th Mar 201710:44 amRNSPublication in the Journal Nature Communications
23rd Mar 20171:47 pmRNSDirector Dealings
22nd Mar 20177:00 amRNSHolding(s) in Company
16th Mar 20177:00 amRNSPRELIMINARY RESULTS FOR THE YEAR ENDED 31 DEC 2016
10th Mar 20177:00 amRNSNotice of Preliminary Results
1st Mar 201710:24 amRNSTotal Voting Rights
28th Feb 20177:00 amRNSAppointment of New Chief Financial Officer
24th Feb 20179:36 amRNSDirector Dealings
24th Feb 20177:00 amRNSResults of TroVax® in Advanced Colorectal Cancer
1st Feb 201710:09 amRNSTotal Voting Rights
25th Jan 20179:02 amRNSDirector/PDMR Shareholding
24th Jan 20174:34 pmRNSDirector Dealings / Market Share Purchase
24th Jan 20179:31 amRNSDirector/PDMR Shareholding
23rd Jan 20179:57 amRNSDirector/PDMR Shareholding
3rd Jan 20179:30 amRNSBlock Listing Return
3rd Jan 20179:28 amRNSTotal Voting Rights
20th Dec 20168:57 amRNSDirector/PDMR Shareholding
12th Dec 201610:52 amRNSBlock listing application
6th Dec 20169:15 amRNSDirector/PDMR Shareholding
5th Dec 201610:25 amRNSFindings Reported by Novartis on CTL-019 at ASH
5th Dec 20169:43 amRNSDirector/PDMR Shareholding
1st Dec 20169:27 amRNSTotal Voting Rights
29th Nov 20167:00 amRNSStrategic Alliance with Orchard Therapeutics
28th Nov 201610:06 amRNSDirector/PDMR Shareholding
8th Nov 20166:28 pmRNSGrant of options (Replacement)
8th Nov 20166:13 pmRNSGrant of options
1st Nov 201610:21 amRNSTotal Voting Rights
25th Oct 20164:40 pmRNSDirector/PDMR Shareholding
10th Oct 20167:21 amRNSPublication of RetinoStat® (OXB-201) Phase I study
6th Oct 20169:24 amRNSHolding(s) in Company
5th Oct 201610:17 amRNSHolding(s) in Company
4th Oct 201611:57 amRNSHolding(s) in Company
4th Oct 20168:16 amRNSAdmission to Trading and Total Voting Rights
29th Sep 201612:27 pmRNSResult of General Meeting and Directors Dealing
26th Sep 201611:00 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.